Table 1

Clinical and cytogenetic findings

CaseAge/sexDiagnosisSplenomegalyBCR-ABL1*Karyotype
159/FCML-TNoPos46,XX,t(9;22)(q34;q11.2)[16]/46,XX[4]
257/FCML-TNoPos46,XX,t(9;22)(q34;q11.2)[16]/46,XX[4]
388/MCML-TNoPos46,XY,t(9;22)(q34;q11.2)[20]
472/FCML-TNoPos46,XX,t(9;22)(q34;q11.2)[18]/46,XX[2]
564/MCML-TYes, 3–4 cmPos46,XY,t(9;22)(q34;q11.2)[20]
626/FCML-TNoPosNo growth
759/FCML-T†Yes, by CTPos‡45–46,XX,t(9;22)(q34;q11.2),-10,inc[cp3]‡
Pos§46,XX,add(17)(p12)[17]/46,XX[15]§
847/FCMLYes, to pelvisPosNA
957/MCMLYes, 2 cmPos46,XY,t(9;22)(q34;q11.2)[9]/45,idem,-Y[11]
1052/MCMLNoPos46,XY,t(9;22)(q34;q11.2)[12]/45,idem,-Y[8]
1140/FCMLNoPos46,XX,t(9;22)(q34;q11.2)[20]
1230/MCML-BCNoPos46,XY,t(9;22)(q34;q11.2),inv(17) (p13q23)[19]/47,idem,del(7)(q11.2),+21[2]
  • *By interphase fluorescence in situ hybridisation.

  • †Thrombocytosis developed while on tyrosine kinase inhibitor therapy.

  • ‡At diagnosis.

  • §27 months after initial diagnosis.

  • CML, chronic myelogenous leukaemia in chronic phase; CML-BC, chronic myelogenous leukaemia in blast crisis; CML-T, chronic myelogenous leukaemia with thrombocytosis; F, female; M, male; NA, not available; Pos, positive.